-
2 months ago | 
oncozine.com | Peter Hofland
Sophia Lunt, PhD, an Michigan State University (MSU) professor in biochemistry and molecular biology in the College of Natural Science, and Richard Lunt, PhD, an MSU professor and Johansen-Crosby Endowed Professor in Chemical Engineering in the College of Engineering, along with Vincent Lavallo, PhD, a professor of chemistry at the University of California, Riverside, have combined their expertise to help develop new light-sensitive chemicals, called cyanine-carborane salts, that are used in...
-
2 months ago | 
oncozine.com | Peter Hofland
Upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, to be held April 25-30, 2025, in Chicago, Illinois, include novel data characterizing the preclinical profiles of Nuvalent’s novel ALK-selective inhibitor, neladalkib (NVL-655), and novel ROS1-selective inhibitor, zidesamtinib (NVL-520).
-
Mar 28, 2025 | 
oncozine.com | Peter Hofland
March is Colorectal Cancer (CRC) Awareness Month, and it highlights a disease that affects millions worldwide. Colorectal cancer is the second-leading cause of cancer-related death in the United States, even though it is highly treatable if caught early. However, the American Cancer Society (ACS) estimates that 154,270 adults will be diagnosed with CRC and 52,900 adults will die from CRC in 2025. Currently, >1 in 3 adults (nearly 50 million Americans) are not following screening recommendations.
-
Mar 27, 2025 | 
oncozine.com | Peter Hofland
OST-HER2, an investigational immunotherapy for osteosarcoma being developed by OS Therapies, is featured in the upcoming documentary Shelter Me: The Cancer Pioneers. Shelter Me, an Emmy Award-winning PBS series, tells uplifting stories about animals and the people who love them.
-
Mar 27, 2025 | 
oncozine.com | Peter Hofland
Scientists from Johns Hopkins Medicine and eight other institutions in the United States, Africa and Europe say they have identified a potential new gene target that could be edited to treat sickle cell disease or SCD, an inherited blood disorder marked by sickle-shaped red blood cells that cause intense pain and shorten lifespans. SCD is an inherited blood disorder that causes red blood cells to become hard, sticky, and sickle-shaped.
-
Mar 27, 2025 | 
oncozine.com | Peter Hofland
Golidocitinib (DZD4205, previously known as AZD4205), an orally available, potent and highly selective Janus kinase 1 (JAK1) inhibitor being developed by Shanghai-based Dizal Pharmaceuticals and approved by the National Medical Products Administration (NMPA) of China for the treatment of relapsed or refractory Peripheral T-cell lymphomas (PTCLs), a group of rare blood cancers, showed synergistic anti-tumor effects in anti-PD-1-resistant non-small cell lung cancer (NSCLC), the most common type...
-
Feb 5, 2025 | 
oncozine.com | Peter Hofland
With nearly 60,000 people being diagnosed with oral cancer (cancer in the oral cavity or oropharyngeal region) in the U.S. every year, and more than 375,000 cases globally, the disease is a significant health concern and remains, according to the American Cancer Society (ACS), the sixth most common cancer worldwide with the rate of new cases continuing to rise.[1].
-
Dec 27, 2024 | 
oncozine.com | Peter Hofland
Datopotamab deruxtecan (Datroway®; Daiichi Sankyo, previously known as DS-1062 and TROP2 ADC, see ADC Drug Map) an antibody-drug conjugate or ADC, being jointly developed and commercialized globally by Daiichi Sankyo and AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.
-
Dec 25, 2024 | 
oncozine.com | Peter Hofland
Coffee and tea are widely consumed around the world and for decades researchers have attempted to investigate and analyze the protective health benefits of them. Although the association between health and coffee and tea consumption is not new, there are still no conclusive answers. [1]What is clear is that numerous studies have shown that coffee drinking is associated with an overall lower risk of dying from all causes of death.
-
Dec 24, 2024 | 
oncozine.com | Peter Hofland
Monotherapy of Imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor, significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations.
